208 related articles for article (PubMed ID: 1620246)
1. Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.
Maldonado R; Fournié-Zaluski MC; Roques BP
Naunyn Schmiedebergs Arch Pharmacol; 1992 Apr; 345(4):466-72. PubMed ID: 1620246
[TBL] [Abstract][Full Text] [Related]
2. Comparison of selective and complete inhibitors of enkephalin-degrading enzymes on morphine withdrawal syndrome.
Maldonado R; Daugé V; Callebert J; Villette JM; Fournié-Zaluski MC; Feger J; Roques BP
Eur J Pharmacol; 1989 Jun; 165(2-3):199-207. PubMed ID: 2776828
[TBL] [Abstract][Full Text] [Related]
3. Differences in physical dependence induced by selective mu or delta opioid agonists and by endogenous enkephalins protected by peptidase inhibitors.
Maldonado R; Feger J; Fournié-Zaluski MC; Roques BP
Brain Res; 1990 Jun; 520(1-2):247-54. PubMed ID: 2169953
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of enkephalinase activity attenuates naloxone-precipitated withdrawal symptoms.
Haffmans J; Dzoljic MR
Gen Pharmacol; 1987; 18(1):103-5. PubMed ID: 3549428
[TBL] [Abstract][Full Text] [Related]
5. Phelorphan, an inhibitor of enzymes involved in the biodegradation of enkephalins, affected the withdrawal symptoms in chronic morphine-dependent rats.
Haffmans J; Walsum MV; van Amsterdam JC; Dzoljic MR
Neuroscience; 1987 Jul; 22(1):233-6. PubMed ID: 2888045
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
Maldonado R; Valverde O; Ducos B; Blommaert AG; Fournie-Zaluski MC; Roques BP
Br J Pharmacol; 1995 Mar; 114(5):1031-9. PubMed ID: 7780637
[TBL] [Abstract][Full Text] [Related]
7. Effects of peptidase inhibitors, [D-Ala2, Met5]-enkephalinamide and antiserum to methionine-enkephalin microinjected into the caudal periaqueductal gray on morphine withdrawal in rats.
Fukunaga Y; Inoue N; Miyamoto M; Kishioka S; Yamamoto H
Jpn J Pharmacol; 1998 Dec; 78(4):455-61. PubMed ID: 9920202
[TBL] [Abstract][Full Text] [Related]
8. The effects of orally active enkephalinase inhibitors on morphine withdrawal syndrome.
Dzoljic MR; Bokszanska A; Korenhof AM; Kaplan CD; Dzoljic M; Rupreht J; Zijlstra FJ; Brinkman EC; Cappendijk SL
Neuroreport; 1992 Jul; 3(7):637-40. PubMed ID: 1421123
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan.
Livingston SJ; Sewell RD; Rooney KF; Smith HJ
Psychopharmacology (Berl); 1988; 94(4):540-4. PubMed ID: 3131801
[TBL] [Abstract][Full Text] [Related]
10. Time course of morphine withdrawal and preproenkephalin gene expression in the periaqueductal gray of rats.
Fukunaga Y; Nishida S; Inoue N; Miyamoto M; Kishioka S; Yamamoto H
Brain Res Mol Brain Res; 1998 Apr; 55(2):221-31. PubMed ID: 9582424
[TBL] [Abstract][Full Text] [Related]
11. The effects of D-phenylalanine and its derivatives on enkephalin degradation in vitro: relation to analgesia and attenuation of the morphine withdrawal syndrome.
Janicki PK; Gumułka SW; Szreniawski Z; Paulo EA; Arnold Z
Pol J Pharmacol Pharm; 1986; 38(1):41-9. PubMed ID: 3763485
[TBL] [Abstract][Full Text] [Related]
12. Analgesic responses elicited by endogenous enkephalins (protected by mixed peptidase inhibitors) in a variety of morphine-sensitive noxious tests.
Schmidt C; Peyroux J; Noble F; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1991 Jan; 192(2):253-62. PubMed ID: 2032557
[TBL] [Abstract][Full Text] [Related]
13. Increase of preproenkephalin mRNA in the caudal part of periaqueductal gray by morphine withdrawal in rats: a quantitative in situ hybridization study.
Fukunaga Y; Nishida S; Inoue N; Kishioka S; Yamamoto H
Brain Res Mol Brain Res; 1996 Nov; 42(1):128-30. PubMed ID: 8915589
[TBL] [Abstract][Full Text] [Related]
14. Enkephalinase inhibitors attenuate naloxone-precipitated withdrawal syndrome.
Dzoljic MR
NIDA Res Monogr; 1986; 75():575-8. PubMed ID: 3123978
[TBL] [Abstract][Full Text] [Related]
15. Naloxone-induced withdrawal syndrome after administration of selective opioid agonists or after activation of the endogenous enkephalinergic system.
Maldonado R; Waksman G; Feger J; Roques BP
Prog Clin Biol Res; 1990; 328():531-4. PubMed ID: 2154817
[No Abstract] [Full Text] [Related]
16. Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation.
Maldonado R; Valverde O; Turcaud S; Fournié-Zaluski MC; Roques BP
Pain; 1994 Jul; 58(1):77-83. PubMed ID: 7970841
[TBL] [Abstract][Full Text] [Related]
17. Comparative study in mice of flunitrazepam vs. diazepam on morphine withdrawal syndrome.
Gibert-Rahola J; Maldonado R; Micó JA; Leonsegui I; Saavedra MC
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):927-33. PubMed ID: 3241876
[TBL] [Abstract][Full Text] [Related]
18. Effects of harman and harmine on naloxone-precipitated withdrawal syndrome in morphine-dependent rats.
Aricioglu-Kartal F; Kayir H; Tayfun Uzbay I
Life Sci; 2003 Sep; 73(18):2363-71. PubMed ID: 12941438
[TBL] [Abstract][Full Text] [Related]
19. Protein kinases in the locus coeruleus and periaqueductal gray matter are involved in the expression of opiate withdrawal.
Maldonado R; Valverde O; Garbay C; Roques BP
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):565-75. PubMed ID: 8751087
[TBL] [Abstract][Full Text] [Related]
20. Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101.
Noble F; Coric P; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1992 Nov; 223(1):91-6. PubMed ID: 1478261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
